The neurosurgical management of optic glioma

1982 ◽  
Vol 57 (4) ◽  
pp. 452-458 ◽  
Author(s):  
Robert T. Tenny ◽  
Edward R. Laws ◽  
Brian R. Younge ◽  
James A. Rush
Keyword(s):  
Survival Rate ◽  
Optic Nerve ◽  
Optic Chiasm ◽  
Optic Glioma ◽  
Review Of The Literature ◽  
Term Survival ◽  
Long Term Survival ◽  
Content Type ◽  
Fine Print

✓ A series of 104 patients with surgically verified optic nerve gliomas is presented. Anterior lesions primarily affecting the optic nerve were present in 42 patients, who have a long-term survival rate of 85.5%. Posterior lesions primarily affecting the optic chiasm were present in 62 patients, most of whom underwent radiation therapy postoperatively, and they have a long-term survival rate of 50%. Unequivocal signs of neurofibromatosis were present in 14%. On the basis of these findings and a review of the literature, recommendations are made for the surgical management of these tumors.

Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy

1998 ◽  
Vol 89 (1) ◽  
pp. 60-68 ◽  
Author(s):  
Richard B. Schwartz ◽  
B. Leonard Holman ◽  
Joseph F. Polak ◽  
Basem M. Garada ◽  
Marc S. Schwartz ◽  
...  
Keyword(s):  
Survival Rate ◽  
Glioblastoma Multiforme ◽  
Single Photon ◽  
Photon Emission ◽  
High Dose ◽  
Term Survival ◽  
Content Type ◽  
Dual Isotope ◽  
Fine Print

Object. The study was conducted to determine the association between dual-isotope single-photon emission computerized tomography (SPECT) scanning and histopathological findings of tumor recurrence and survival in patients treated with high-dose radiotherapy for glioblastoma multiforme. Methods. Studies in which SPECT with 201Tl and 99mTc-hexamethypropyleneamine oxime (HMPAO) were used were performed 1 day before reoperation in 47 patients with glioblastoma multiforme who had previously been treated by surgery and high-dose radiotherapy. Maximum uptake of 201Tl in the lesion was expressed as a ratio to that in the contralateral scalp, and uptake of 99mTc-HMPAO was expressed as a ratio to that in the cerebellar cortex. Patients were stratified into groups based on the maximum radioisotope uptake values in their tumor beds. The significance of differences in patient gender, histological characteristics of tissue at reoperation, and SPECT uptake group with respect to 1-year survival was elucidated by using the chi-square statistic. Comparisons of patient ages and time to tumor recurrence as functions of 1-year survival were made using the t-test. Survival data at 1 year were presented according to the Kaplan—Meier method, and the significance of potential differences was evaluated using the log-rank method. The effects of different variables (tumor type, time to recurrence, and SPECT grouping) on long-term survival were evaluated using Cox proportional models that controlled for age and gender. All patients in Group I (201Tl ratio < 2 and 99mTc-HMPAO ratio < 0.5) showed radiation changes in their biopsy specimens: they had an 83.3% 1-year survival rate. Group II patients (201T1 ratio < 2 and 99mTc-HMPAO ratio of ≥ 0.5 or 201Tl ratio between 2 and 3.5 regardless of 99mTc-HMPAO ratio) had predominantly infiltrating tumor (66.6%); they had a 29.2% 1-year survival rate. Almost all of the patients in Group III (201Tl ratio > 3.5 and 99mTc-HMPAO ratio ≥ 0.5) had solid tumor (88.2%) and they had a 6.7% 1-year survival rate. Histological data were associated with 1-year survival (p < 0.01); however, SPECT grouping was more closely associated with 1-year survival (p < 0.001) and was the only variable significantly associated with long-term survival (p < 0.005). Conclusions. Dual-isotope SPECT data correlate with histopathological findings made at reoperation and with survival in patients with malignant gliomas after surgical and high-dose radiation therapy.

The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme

2004 ◽  
Vol 101 (2) ◽  
pp. 219-226 ◽  
Author(s):  
Naoki Shinojima ◽  
Masato Kochi ◽  
Jun-Ichiro Hamada ◽  
Hideo Nakamura ◽  
Shigetoshi Yano ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Giant Cell ◽  
Adult Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Content Type ◽  
Free Interval ◽  
Younger Age ◽  
Fine Print

Object. Glioblastoma multiforme (GBM) remains incurable by conventional treatments, although some patients experience long-term survival. A younger age, a higher Karnofsky Performance Scale (KPS) score, more aggressive treatment, and long progression-free intervals have been reported to be positively associated with long-term postoperative patient survival. The aim of this retrospective study was the identification of additional favorable prognostic factors affecting long-term survival in surgically treated adult patients with supratentorial GBM. Methods. Of 113 adult patients newly diagnosed with histologically verified supratentorial GBM who were enrolled in Phase III trials during the period between 1987 and 1998, six (5.3%) who survived for longer than 5 years were defined as long-term survivors, whereas the remaining 107 patients served as controls. All six were women and were compared with the controls; they were younger (mean age 44.2 years, range 31–60 years), and their preoperative KPS scores were higher (mean 85, range 60–100). Four of the six patients underwent gross-total resection. In five patients (83.3%) the progression-free interval was longer than 5 years and in three a histopathological diagnosis of giant cell GBM was made. This diagnosis was not made in the other 107 patients. Conclusions. Among adult patients with supratentorial GBM, female sex and histopathological characteristics consistent with giant cell GBM may be predictive of a better survival rate, as may traditional factors (that is, younger age, good KPS score, more aggressive resection, and a long progression-free interval).

Multiple intracranial metastases of malignant melanoma with long-term survival

1984 ◽  
Vol 60 (3) ◽  
pp. 621-624 ◽  
Author(s):  
Eduardo Fernandez ◽  
Giulio Maira ◽  
Alfredo Puca ◽  
Andrea Vignati
Keyword(s):  
Malignant Melanoma ◽  
Brain Metastases ◽  
Term Survival ◽  
Long Term Survival ◽  
Content Type ◽  
Multiple Brain Metastases ◽  
Intracranial Metastases ◽  
Fine Print

✓ The authors present a case of multiple brain metastases and an extracranial secondary localization from malignant melanoma. The patient was operated on three times for the intracranial masses and had a 49-month survival with a good quality of life after the first of the three operations. She lived a total of 80 months from the time of diffusion of the primary tumor. The course of malignant melanoma is unpredictable, and long-term survival can be achieved in some cases, even in the presence of multiple brain metastases.

Malignant transformation of ganglioneuroma into spinal neuroblastoma in an adult

1998 ◽  
Vol 88 (2) ◽  
pp. 324-327 ◽  
Author(s):  
Abhaya V. Kulkarni ◽  
Juan M. Bilbao ◽  
Michael D. Cusimano ◽  
Paul J. Muller
Keyword(s):  
Malignant Transformation ◽  
Benign Tumor ◽  
Ganglion Cells ◽  
Term Survival ◽  
Long Term Survival ◽  
Content Type ◽  
First Report ◽  
Fine Print

✓ Ganglioneuroma is generally considered to be a benign tumor and potentially surgically curable. The authors present a case of a 21-year-old woman who underwent resection of a retroperitoneal ganglioneuroma and developed spinal neuroblastoma 11 years later. She has survived 10 more years with only recent development of metastases. To the authors' knowledge, this is the first report of malignant transformation of a ganglioneuroma into a neuroblastoma. Also, such long-term survival in an adult with spinal neuroblastoma has not been reported previously. This case raises the possibility of a dedifferentiating potential for ganglion cells in a ganglioneuroma or the presence of a long-term, quiescent form of neuroblastoma.

Long-term survival of patients treated with BCNU for brain tumors

1975 ◽  
Vol 43 (2) ◽  
pp. 191-196 ◽  
Author(s):  
John Calogero ◽  
David C. Crafts ◽  
Charles B. Wilson ◽  
Edwin B. Boldrey ◽  
Alan Rosenberg ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Potential Role ◽  
Term Survival ◽  
Glial Tumors ◽  
Long Term Survival ◽  
Content Type ◽  
Fine Print

✓The authors present three patients who, after excision and irradiation of their brain tumors, were treated with BCNU for recurrence. All three patients responded well and now are without evidence of tumor, 37, 30, and 36 months after BCNU was stopped. Although these patients represent only a small fraction of those treated with BCNU, they indicate the potential role of chemotherapy in the management of glial tumors.

Deformity correction and long-term survival in an infant with iniencephaly

1991 ◽  
Vol 75 (1) ◽  
pp. 126-130 ◽  
Author(s):  
John J. Gartman ◽  
Thomas E. Melin ◽  
W. Thomas Lawrence ◽  
Stephen K. Powers
Keyword(s):  
Deformity Correction ◽  
Male Infant ◽  
Term Survival ◽  
Long Term Survival ◽  
Content Type ◽  
Cervical Deformity ◽  
Neurosurgical Intervention ◽  
Fine Print

✓ The authors describe the case of a male infant who was diagnosed prenatally as having iniencephaly. Since birth, the child has grown, thrived, and undergone two successful operations to correct his cervical deformity. This case demonstrates that the iniencephaly defect is not uniformly fatal and that neurosurgical intervention may offer significant improvement in the cervical deformity.

Visual changes after gamma knife surgery for optic nerve tumors

2005 ◽  
Vol 102 (Special_Supplement) ◽  
pp. 143-146 ◽  
Author(s):  
Yang Kwon ◽  
Jun Seok Bae ◽  
Jae Myung Kim ◽  
Do Hee Lee ◽  
Soon Young Kim ◽  
...  
Keyword(s):  
Optic Nerve ◽  
Gamma Knife ◽  
Gamma Knife Surgery ◽  
Optic Glioma ◽  
Content Type ◽  
Nerve Sheath ◽  
Optic Nerve Sheath Meningioma ◽  
Optic Nerve Tumors ◽  
Visual Changes ◽  
Fine Print

✓ Tumors involving the optic nerve (optic glioma, optic nerve sheath meningioma) are benign but difficult to treat. Gamma knife surgery (GKS) may be a useful treatment. The authors present data obtained in three such cases and record the effects of GKS.

scholarly journals The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review

2021 ◽  
Vol 28 ◽  
pp. 107327482199743
Author(s):  
Ke Chen ◽  
Xiao Wang ◽  
Liu Yang ◽  
Zheling Chen
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Survival Rate ◽  
Meta Analysis ◽  
Response Rates ◽  
Control Group ◽  
Term Survival ◽  
Long Term Survival ◽  
And Control

Background: Treatment options for advanced gastric esophageal cancer are quite limited. Chemotherapy is unavoidable at certain stages, and research on targeted therapies has mostly failed. The advent of immunotherapy has brought hope for the treatment of advanced gastric esophageal cancer. The aim of the study was to analyze the safety of anti-PD-1/PD-L1 immunotherapy and the long-term survival of patients who were diagnosed as gastric esophageal cancer and received anti-PD-1/PD-L1 immunotherapy. Method: Studies on anti-PD-1/PD-L1 immunotherapy of advanced gastric esophageal cancer published before February 1, 2020 were searched online. The survival (e.g. 6-month overall survival, 12-month overall survival (OS), progression-free survival (PFS), objective response rates (ORR)) and adverse effects of immunotherapy were compared to that of control therapy (physician’s choice of therapy). Results: After screening 185 studies, 4 comparative cohort studies which reported the long-term survival of patients receiving immunotherapy were included. Compared to control group, the 12-month survival (OR = 1.67, 95% CI: 1.31 to 2.12, P < 0.0001) and 18-month survival (OR = 1.98, 95% CI: 1.39 to 2.81, P = 0.0001) were significantly longer in immunotherapy group. The 3-month survival rate (OR = 1.05, 95% CI: 0.36 to 3.06, P = 0.92) and 18-month survival rate (OR = 1.44, 95% CI: 0.98 to 2.12, P = 0.07) were not significantly different between immunotherapy group and control group. The ORR were not significantly different between immunotherapy group and control group (OR = 1.54, 95% CI: 0.65 to 3.66, P = 0.01). Meta-analysis pointed out that in the PD-L1 CPS ≥10 sub group population, the immunotherapy could obviously benefit the patients in tumor response rates (OR = 3.80, 95% CI: 1.89 to 7.61, P = 0.0002). Conclusion: For the treatment of advanced gastric esophageal cancer, the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy was superior to that of chemotherapy or palliative care.

Sign in / Sign up

Export Citation Format

Share Document